{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:04:30Z","timestamp":1788383070954,"version":"build-2803163510"},"reference-count":37,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are major drivers of morbidity, mortality, disease progression, and healthcare utilization worldwide. Evolving definitions of COPD and exacerbations, along with emerging evidence on risk stratification and treatment optimization, have prompted updates in clinical practice, most recently reflected in the 2026 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. This review summarizes contemporary perspectives on AECOPD, with a focus on updated definitions, epidemiology, predictors, clinical impact, and current pharmacological and nonpharmacological management strategies, including emerging preventive therapies. A narrative review of published literature, international guidelines, and major clinical trials was conducted, emphasizing evidence relevant to the assessment, treatment, and prevention of AECOPD. Particular attention was given to severity classification and guideline-directed therapeutic approaches. AECOPD is associated with substantial short- and long-term mortality, accelerated lung function decline, increased cardiovascular risk, and high readmission rates. The 2026 GOLD guidelines lower the threshold for high-risk classification, recognizing that even a single moderate exacerbation increases future risk. Acute management remains centered on short-acting bronchodilators, short courses of systemic corticosteroids, and antibiotics when indicated, with treatment of intensity guided by clinical severity and physiological derangements. Adjunctive supportive measures and early postdischarge interventions are critical to improving outcomes. While biologics, macrolides, Roflumilast, and Ensifentrine have no established role in the acute setting, they play an important role in exacerbation prevention as part of individualized, biomarker-informed maintenance strategies. AECOPD should be viewed as a sentinel event that necessitates both effective acute management and reassessment of long-term therapy. Early intervention, severity-based treatment, and postexacerbation optimization of maintenance therapy are essential to reduce recurrence, limit disease progression, and improve survival and quality of life in patients with COPD.<\/jats:p>","DOI":"10.1055\/a-2826-5752","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:13:07Z","timestamp":1773792787000},"page":"298-307","source":"Crossref","is-referenced-by-count":1,"title":["Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Pharmacological Treatment of AECOPD New Perspectives"],"prefix":"10.1055","volume":"47","author":[{"given":"Jonathan","family":"Calvello","sequence":"additional","affiliation":[{"name":"Department of Medicine, Northwell Northern Westchester Hospital, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Avaricio","sequence":"additional","affiliation":[{"name":"Department of Medicine, Northwell Northern Westchester Hospital, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ruggeri","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Biomedical Sciences, Dental Sciences & Morpho-Functional Imaging, University of Messina, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio M.","family":"Esquinas","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, Hospital Morales Meseguer, NIV-ICU Group, Biomedical Research Institute Pascual Parrilla\u2013IMIB, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushra","family":"Mina","sequence":"additional","affiliation":[{"name":"Division, Pulmonary Critical Care and Sleep Medicine, Department of Medicine, Northwell Northern Westchester Hospital, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"11","key":"ref1","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1164\/rccm.202204-0671PP","article-title":"Definition and nomenclature of chronic obstructive pulmonary disease: time for its revision","volume":"206","author":"B Celli","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(25)00432-1","article-title":"GOLD COPD report: 2026 update","author":"P Venkatesan","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"08","key":"ref3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S2213-2600(24)00339-4","article-title":"The global burden of COPD: epidemiology and effect of prevention strategies","volume":"13","author":"M M de Oca","year":"2025","journal-title":"Lancet Respir Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"e069679","DOI":"10.1136\/bmj-2021-069679","article-title":"Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the global burden of disease study 2019","volume":"378","author":"S Safiri","year":"2022","journal-title":"BMJ"},{"issue":"06","key":"ref5","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.rmed.2011.01.008","article-title":"Lower limit of normal or FEV1\/FVC\u2009<\u20090.70 in diagnosing COPD: an evidence-based review","volume":"105","author":"Hoesein FA Mohamed","year":"2011","journal-title":"Respir Med"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1183\/20734735.0346-2018","article-title":"Under- and over-diagnosis of COPD: a global perspective","volume":"15","author":"T Ho","year":"2019","journal-title":"Breathe (Sheff)"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1465-9921-13-13","article-title":"\u201cGOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study.\u201d","volume":"13","author":"G G\u00fcder","year":"2012","journal-title":"Respir Res"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S2213-2600(21)00511-7","article-title":"Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis","volume":"10","author":"D Adeloye","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"05","key":"ref10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S2213-2600(21)00506-3","article-title":"Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment","volume":"10","author":"I A Yang","year":"2022","journal-title":"Lancet Respir Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(25)01637-X","article-title":"Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","author":"S I Hay","year":"2025","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(25)01917-8","article-title":"Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","author":"M Naghavi","year":"2025","journal-title":"Lancet"},{"issue":"13","key":"ref15","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMra1900500","article-title":"Update on clinical aspects of chronic obstructive pulmonary disease","volume":"381","author":"B R Celli","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"e109721","DOI":"10.1371\/journal.pone.0109721","article-title":"Predictors of exacerbations in chronic obstructive pulmonary disease\u2013results from the Bergen COPD cohort study","volume":"9","author":"G R Huseb\u00f8","year":"2014","journal-title":"PLoS One"},{"issue":"02","key":"ref17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.rmed.2014.12.006","article-title":"Characterisation of the frequent exacerbator phenotype in COPD patients in a large UK primary care population","volume":"109","author":"L McGarvey","year":"2015","journal-title":"Respir Med"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"e0208847","DOI":"10.1371\/journal.pone.0208847","article-title":"Treatment strategies after acute exacerbations of chronic obstructive pulmonary disease: impact on mortality","volume":"13","author":"F Casas-Mendez","year":"2018","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/COPD.S438893","article-title":"Risk of death and cardiovascular events following an exacerbation of COPD: the EXACOS-CV US study","volume":"19","author":"K Daniels","year":"2024","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"03","key":"ref20","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1183\/09031936.00043710","article-title":"Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach","volume":"37","author":"M Hoogendoorn","year":"2011","journal-title":"Eur Respir J"},{"issue":"07","key":"ref21","doi-asserted-by":"crossref","first-page":"e097006","DOI":"10.1136\/bmjopen-2024-097006","article-title":"Future exacerbations and mortality rates among patients experiencing COPD exacerbations: a meta-analysis of results from the EXACOS\/AVOIDEX programme","volume":"15","author":"K Rhodes","year":"2025","journal-title":"BMJ Open"},{"issue":"04","key":"ref22","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1164\/rccm.201710-2029OC","article-title":"Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease","volume":"198","author":"K J Rothnie","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"09","key":"ref23","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1164\/rccm.202209-1795CI","article-title":"Differential diagnosis of suspected chronic obstructive pulmonary disease exacerbations in the acute care setting: best practice","volume":"207","author":"B R Celli","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"03","key":"ref24","doi-asserted-by":"crossref","first-page":"1602265","DOI":"10.1183\/13993003.02265-2016","article-title":"Prevention of COPD exacerbations: a European Respiratory Society\/American Thoracic Society guideline","volume":"50","author":"J A Wedzicha","year":"2017","journal-title":"Eur Respir J"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"107090","DOI":"10.1016\/j.rmed.2022.107090","article-title":"Readmission rate for acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"206","author":"H Ruan","year":"2023","journal-title":"Respir Med"},{"issue":"48","key":"ref26","doi-asserted-by":"crossref","first-page":"e40483","DOI":"10.1097\/MD.0000000000040483","article-title":"Readmission rates within the first 30 and 90 days after severe COPD exacerbations (RACE study)","volume":"103","author":"O Baydar Toprak","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"07","key":"ref27","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1513\/AnnalsATS.201712-913OC","article-title":"Early hospital readmissions after an acute exacerbation of chronic obstructive pulmonary disease in the nationwide readmissions database","volume":"15","author":"D M Jacobs","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.2147\/COPD.S554744","article-title":"Validation study of Rome criteria for assessing COPD exacerbation severity and predicting clinical outcomes: Turkish Thoracic Society COPD assembly","volume":"20","author":"A Baha","year":"2025","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"1600791","DOI":"10.1183\/13993003.00791-2016","article-title":"Management of COPD exacerbations: a European Respiratory Society\/American Thoracic Society guideline","volume":"49","author":"J A Wedzicha","year":"2017","journal-title":"Eur Respir J"},{"issue":"06","key":"ref31","doi-asserted-by":"crossref","first-page":"413","DOI":"10.7326\/M19-3007","article-title":"Pharmacologic therapies in patients with exacerbation of chronic obstructive pulmonary disease: a systematic review with meta-analysis","volume":"172","author":"C C Dobler","year":"2020","journal-title":"Ann Intern Med"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2466-4-13","article-title":"Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease","volume":"4","author":"P N Black","year":"2004","journal-title":"BMC Pulm Med"},{"issue":"03","key":"ref33","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1378\/chest.08-1516","article-title":"Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis","volume":"135","author":"J Rizkallah","year":"2009","journal-title":"Chest"},{"issue":"07","key":"ref34","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1164\/rccm.201901-0094OC","article-title":"Azithromycin during acute chronic obstructive pulmonary disease exacerbations requiring hospitalization (BACE). A multicenter, randomized, double-blind, placebo-controlled trial","volume":"200","author":"K Vermeersch","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"16","key":"ref35","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1007\/s11606-022-07486-5","article-title":"Azithromycin versus beta-lactams in hospitalized patients with acute exacerbations of COPD","volume":"37","author":"N Baalbaki","year":"2022","journal-title":"J Gen Intern Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.2147\/COPD.S550144","article-title":"Multi-criteria decision analysis of biologics in chronic obstructive pulmonary disease","volume":"20","author":"M G Matera","year":"2025","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"01","key":"ref37","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S2213-2600(24)00299-6","article-title":"Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial","volume":"13","author":"S Ramakrishnan","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"17","key":"ref38","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1056\/NEJMoa2413181","article-title":"Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype","volume":"392","author":"F C Sciurba","year":"2025","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/COPD.S385811","article-title":"Perspectives on ensifentrine and its therapeutic potential in the treatment of COPD: evidence to date","volume":"19","author":"M A Faruqi","year":"2024","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"04","key":"ref40","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1164\/rccm.202306-0944OC","article-title":"Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE trials)","volume":"208","author":"A Anzueto","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1177\/14799731251314874","article-title":"Ensifentrine in COPD patients taking long-acting bronchodilators: a pooled post-hoc analysis of the ENHANCE-1\/2 studies","volume":"22","author":"M Dransfield","year":"2025","journal-title":"Chron Respir Dis"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2826-5752.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T22:49:11Z","timestamp":1781218151000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2826-5752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":37,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2026,6,11]]},"published-print":{"date-parts":[[2026,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2826-5752","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,17]]},"published":{"date-parts":[[2026,3,17]]}}}